Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| KU Leuven | OTHER |
| Hasselt University | OTHER |
| Ziekenhuis Oost-Limburg | OTHER |
| Jessa Hospital |
Not provided
Not provided
Not provided
Not provided
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transplanted patients | All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven |
| |
| Transplanted patients with past SARS-CoV-2 infection | Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity |
| |
| Transplanted patients without past SARS-CoV-2 infection | 100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SARS-CoV-2 IgG | Diagnostic Test | Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence and risk-factors for SARS-CoV-2 infection | Prevalence and risk-factors for SARS-CoV-2 infection | inclusion during 4 months |
| Prevalence and risk-factors for COVID-19 | Prevalence and risk-factors for COVID-19 | inclusion during 4 months |
| Measure | Description | Time Frame |
|---|---|---|
| Durability of IgG positivity | Durability of IgG positivity/immunity | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
all patients who underwent solid organ or hematopoietic transplantation at UZ Leuven and who give informed consent
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jef Verbeek, MD, PhD | Contact | + 32 16 34 42 25 | jef.verbeek@uzleuven.be | |
| Natalie Van den Ende | Contact | +32 16 340749 | natalie.vandenende@uzleuven.be |
| Name | Affiliation | Role |
|---|---|---|
| Jef Verbeek, MD, PhD | UZ Leuven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UZ Leuven | Recruiting | Leuven | Vlaams Brabant | 3000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D045169 | Severe Acute Respiratory Syndrome |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Collection and storage plasma samples
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |